What FDA Approvals Really Tell Us About the State of Biopharmaceutical Innovation

The FDA approved 37 novel medicines in 2022, a figure that sits modestly above the historical average. On the surface, it is an encouraging statistic. Beneath the headline, however, it tells a much more interesting story.

Given the disruption caused by the COVID-19 pandemic, this level of productivity was far from inevitable.

Clinical trial recruitment slowed dramatically during 2020 and 2021. Healthcare systems redirected resources toward pandemic response. Patients delayed routine medical care. Supply chains became strained, and many development programs experienced operational delays.

Yet despite these headwinds, the biopharmaceutical industry continued delivering a steady stream of new therapies to patients.

To me, this highlights something important about today's innovation ecosystem.

Modern drug development has become remarkably resilient.

The industry's growing reliance on external innovation, strategic partnerships, contract development and manufacturing organizations, specialized CROs, advanced analytics, and increasingly sophisticated digital tools has created a more distributed model of innovation than existed a decade ago. Rather than relying exclusively on vertically integrated pharmaceutical organizations, today's pipeline is supported by a global network of biotechnology companies, academic institutions, platform technology providers, and commercial partners.

The approval count also reminds us that innovation should never be measured by quantity alone.

Some approvals represent incremental improvements. Others establish entirely new therapeutic modalities or validate technologies capable of generating many future medicines. Gene therapies, RNA therapeutics, precision oncology, and next-generation biologics continue to expand what is scientifically possible while creating new opportunities for platform companies and external innovation.

Looking ahead, I believe the most meaningful metric will not simply be how many medicines receive approval each year.

It will be how effectively our innovation ecosystem continues to translate advances in biology, artificial intelligence, engineering, and computational science into therapies that meaningfully improve patients' lives.

Approval numbers provide an important snapshot, but the real story is the strength, adaptability, and continued evolution of the engine that produces them.